FDA rejects motavizumab again

Tuesday 31 August 2010

The US Food and Drug Administration has issued its second ‘complete response letter’ to the AstraZeneca unit, MedImmune, rejecting its application to market motavizumab, a new monoclonal antibody for respiratory syncytial virus disease.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom